MARKET

BCLI

BCLI

Brainstorm Cell Therapeutics I
NASDAQ
1.520
-0.020
-1.30%
After Hours: 1.570 +0.05 +3.29% 18:25 01/27 EST
OPEN
1.560
PREV CLOSE
1.540
HIGH
1.570
LOW
1.490
VOLUME
152.55K
TURNOVER
0
52 WEEK HIGH
4.700
52 WEEK LOW
1.085
MARKET CAP
55.54M
P/E (TTM)
-2.1758
1D
5D
1M
3M
1Y
5Y
Brainstorm Cell Therapeutics (BCLI) Receives a Buy from Maxim Group
TipRanks · 01/11 19:45
Benzinga Pro's Top 5 Stocks To Watch For Wednesday, January 11, 2023: GOOGL, CHWY, ISRG, BCLI, BWEN
Benzinga · 01/11 14:11
BRIEF-Brainstorm Cell Therapeutics Enters Into Partnerships To Provide Public Access To Biospecimens From Study
Reuters · 01/10 12:25
BrainStorm Cell Therapeutics promotes Stacy Lindborg to co-CEO
Seeking Alpha · 01/04 13:01
BRIEF-BrainStorm Cell Therapeutics Announces Promotion Of Dr. Stacy Lindborg To Co-Chief Executive Officer
Reuters · 01/04 12:34
BRIEF-Brainstorm Cell Therapeutics Says Type A Meeting With FDA Granted For NurOwn
Reuters · 12/27/2022 16:30
BrainStorm gets FDA panel meeting to discuss declined filing for ALS drug NurOwn
Seekingalpha · 12/27/2022 11:20
BrainStorm Cell Therapeutics Announces Type A Meeting With FDA Granted For NurOwn; Meeting Scheduled For Jan. 11, 2023
Benzinga · 12/27/2022 11:01
More
About BCLI
Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is focused on the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases, including Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Progressive Multiple Sclerosis (PMS), Alzheimer's disease (AD), and other neurodegenerative diseases. NurOwn, its cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete high levels of neurotrophic factors (NTFs), modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival and improve neurological function. NurOwn has completed its phase III ALS and phase II PMS clinical trials. Its wholly owned subsidiary, BrainStorm Cell Therapeutics Ltd. holds the rights to commercialize its NurOwn technology. Its other subsidiaries include Advanced Cell Therapies Ltd., and two others.

Webull offers kinds of Brainstorm Cell Therapeutics Inc stock information, including NASDAQ:BCLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BCLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BCLI stock methods without spending real money on the virtual paper trading platform.